TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today that it has signed a collaborative discovery and license agreement with Roche. The collaboration will cover the identification and validation of genetic variations for the prediction of response to drugs used for the treatment of rheumatoid arthritis.
